The new structure includes the creation of a unified Human Foods Program, the adoption of a new model for the FDA's field operations and will mean more inspections for CPGs, according to experts.
Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.